Establishment_NN
and_CC
characterization_NN
of_IN
EBV-positive_JJ
and_CC
EBV-negative_JJ
primary_JJ
effusion_NN
lymphoma_NN
cell_NN
lines_NNS
harbouring_VBG
human_JJ
herpesvirus_NN
type-8_NN
._.

In_IN
this_DT
study_NN
we_PRP
report_VBP
on_IN
the_DT
establishment_NN
and_CC
characterization_NN
of_IN
two_CD
novel_JJ
lymphoma_NN
cell_NN
lines_NNS
-LRB-_-LRB-
CRO-AP\/3_NN
and_CC
CRO-AP\/5_NN
-RRB-_-RRB-
which_WDT
carry_VBP
infection_NN
by_IN
human_JJ
herpesvirus_NN
type-8_NN
-LRB-_-LRB-
HHV-8_NN
-RRB-_-RRB-
and_CC
have_VBP
derived_VBN
from_IN
AIDS-related_JJ
primary_JJ
effusion_NN
lymphoma_NN
-LRB-_-LRB-
PEL_NN
-RRB-_-RRB-
._.

These_DT
two_CD
cell_NN
lines_NNS
are_VBP
representative_JJ
of_IN
different_JJ
virologic_JJ
subtypes_NNS
of_IN
PEL_NN
,_,
i.e._FW
HHV-8_NN
+_CD
\/_:
EBV_NN
-_:
PEL_NN
in_IN
the_DT
case_NN
of_IN
CRO-AP\/3_NN
and_CC
HHV-8_NN
+_CC
\/_JJ
EBV_NN
+_CC
PEL_NN
in_IN
the_DT
case_NN
of_IN
CRO-AP\/5_NN
._.

Consistent_JJ
with_IN
the_DT
diagnosis_NN
of_IN
PEL_NN
,_,
both_CC
CRO-AP\/3_NN
and_CC
CRO-AP\/5_NN
expressed_VBD
indeterminate_JJ
-LRB-_-LRB-
i.e._FW
non-B_JJ
,_,
non-T_JJ
-RRB-_-RRB-
phenotypes_NNS
although_IN
immunogenotypic_JJ
studies_NNS
documented_VBD
their_PRP$
B-cell_NN
origin_NN
._.

Both_DT
cell_NN
lines_NNS
are_VBP
devoid_JJ
of_IN
genetic_JJ
lesions_NNS
of_IN
c-MYC_NN
,_,
BCL-2_NN
and_CC
p53_NN
as_RB
well_RB
as_IN
gross_JJ
rearrangements_NNS
of_IN
BCL-6_NN
._.

Detailed_JJ
histogenetic_JJ
characterization_NN
of_IN
these_DT
novel_JJ
PEL_NN
cell_NN
lines_NNS
suggests_VBZ
that_IN
PEL_NN
may_MD
derive_VB
from_IN
a_DT
post-germinal_JJ
center_NN
B_NN
cell_NN
which_WDT
has_VBZ
undergone_VBN
pre-terminal_JJ
differentiation_NN
._.

The_DT
CRO-AP\/3_NN
and_CC
CRO-AP\/5_NN
cell_NN
lines_NNS
may_MD
provide_VB
a_DT
valuable_JJ
model_NN
for_IN
clarifying_VBG
the_DT
pathogenesis_NN
of_IN
PEL_NN
._.

In_IN
particular_JJ
,_,
these_DT
cell_NN
lines_NNS
may_MD
help_VB
understand_VB
the_DT
relative_JJ
contribution_NN
of_IN
HHV-8_NN
and_CC
EBV_NN
to_TO
PEL_NN
growth_NN
and_CC
development_NN
and_CC
may_MD
facilitate_VB
the_DT
identification_NN
of_IN
recurrent_JJ
cytogenetic_JJ
abnormalities_NNS
highlighting_VBG
putative_JJ
novel_JJ
cancer_NN
related_JJ
loci_NNS
relevant_JJ
to_TO
PEL_NN
._.

